9 July 2018 - CADTH has completed its assessment of Dupixent (dupilumab) for the treatment of patients with atopic dermatitis.

The CADTH CDEC recommends that dupilumab not be reimbursed for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

• No evidence was available that compared dupilumab with other drugs commonly used in the treatment of AD. The four phase III, placebo-controlled, randomized controlled trials (RCTs) (three 16-week trials [SOLO 1, SOLO 2, and LIBERTY AD CAFÉ] and one 52-week trial [LIBERTY AD CHRONOS]) reviewed were not designed to compare dupilumab with other drugs commonly used in the treatment of atopic dermatitis. Although these trials demonstrated that a statistically significantly greater percentage of patients had improvements in AD severity, symptoms, and quality of life with dupilumab treatment compared with placebo, the magnitude of clinical benefit with dupilumab compared with existing alternative treatments is unknown.
  
• There are several notable gaps in the clinical evidence regarding dupilumab, including data to assess the long-term safety of dupilumab, concerns with the generalizability of the trial results to patients who would be expected to use dupilumab in clinical practice, and an absence of efficacy and safety data for the use of dupilumab in patients where topical prescription therapies are not advisable.
  

Read CADTH CDEC final recommendation for dupilumab